Get the Stockscreener App
0.356
3.81%
-0.0141
After Hours:
.33
-0.026
-7.30%
Scienture Holdings Inc stock is traded at $0.356, with a volume of 2.57M.
It is down -3.81% in the last 24 hours and down -5.80% over the past month.
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on the commercialization and development of products for the treatment of cardiovascular (CVS) and Central Nervous System (CNS) diseases. Scienture LLC launched its first commercial product for hypertension and is in the process of commercializing its second product for the treatment of opioid overdose. Its development pipeline consists of a broad range of novel product candidates including new potential treatments for migraine, thrombosis, pain and other related disorders.
See More
Previous Close:
$0.3701
Open:
$0.34
24h Volume:
2.57M
Relative Volume:
2.09
Market Cap:
$14.46M
Revenue:
$656.60K
Net Income/Loss:
$-16.79M
P/E Ratio:
-0.3314
EPS:
-1.0743
Net Cash Flow:
$-11.12M
1W Performance:
+3.07%
1M Performance:
-5.80%
6M Performance:
-34.00%
1Y Performance:
-77.61%
1-Day Range:
$0.3185
$0.36
1-Week Range:
$0.29
$0.385
52-Week Range:
$0.2382
$2.60
Scienture Holdings Inc Stock (SCNX) Company Profile
Name
Scienture Holdings Inc
Sector
Industry
Phone
(800) 261 0281
Address
20 AUSTIN BLVD., COMMACK
Compare SCNX vs HITI, PETS, POM, WGRX
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SCNX
Scienture Holdings Inc
|
0.356 | 15.04M | 656.60K | -16.79M | -11.12M | -1.0743 |
HITI
High Tide Inc
|
2.18 | 194.19M | 486.49M | -33.29M | 10.86M | -0.3627 |
PETS
Petmed Express Inc
|
1.91 | 41.89M | 182.67M | -64.87M | -22.92M | -3.1193 |
POM
Pomdoctor Ltd Adr
|
1.42 | 11.41M | 0 | 0 | 0 | 0.00 |
WGRX
Wellgistics Health Inc
|
2.91 | 7.72M | 14.03M | -76.59M | -13.73M | -41.45 |
Scienture Holdings Inc Stock (SCNX) Latest News
Scienture Holdings Company Profile & Introduction - Moomoo
Scienture Holdings stock jumps over 20% pre-market: Here's why - MSN
Maxim Group Maintains Scienture Holdings(SCNX.US) With Buy Rating, Maintains Target Price $1.5 - Moomoo
Scienture Holdings Stock Jumps Over 20% Pre-Market: Here's Why - Sahm
Scienture Holdings (SCNX) Registration filing Summary - Quartr
The trading volume of these stocks is deviating from the norm in today's session. - ChartMill
Scienture Holdings, Inc. Completes Manufacturing of Commercial Launch Inventory and Begins Shipments of Rezenopy Nasal Spray 10 Mg to U.S. Pharmaceutical Wholesalers - marketscreener.com
Scienture (SCNX) Prepares for Rezonopy Nasal Spray Launch - GuruFocus
Scienture completes manufacturing for naloxone spray launch By Investing.com - Investing.com Canada
Scienture completes manufacturing for naloxone spray launch - Investing.com
SCIENTURE Announces Commercial Inventory Readiness and July Shipments of REZENOPY™ (naloxone hydrochloride) to Wholesalers - marketscreener.com
SCIENTURE Announces Commercial Inventory Readiness and July Shipments of REZENOPY (Naloxone Hydrochloride) to Wholesalers - Moomoo
Scienture Holdings (SCNX) Slips 4% as Stock Tests Key Support Near $0.31Daily Profile - dars.gov.et
Scienture secures $11M debt financing for product launches - Investing.com
SCNX Q1 2026 Earnings: Significant EPS Beat Amid Pre-Revenue Stage as Scienture Outperforms Analyst ExpectationsEPS Surprise History - dars.gov.et
Price to sales forward of Scienture Holdings, Inc. – NASDAQ:SCNX - TradingView
Price to book forward of Scienture Holdings, Inc. – NASDAQ:SCNX - TradingView
Price to earnings forward of Scienture Holdings, Inc. – NASDAQ:SCNX - TradingView
Scienture Holdings, Inc. Actuals & Estimates (NASDAQ:SCNX) - TradingView
SCNX Q1 2026 Earnings: EPS Surprise of 64.35% Amid Revenue Silence; Stock Declines 1.42%Profit Recovery Report - dars.gov.et
SCNX Forecast — Price Target — Prediction for 2027 - TradingView
Scienture Holdings Inc. (SCNX) Q1 2026 Earnings: Narrower-than-Expected Loss Fails to Lift Shares - dars.gov.et
Scienture Holdings Inc (SCNX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Scienture Holdings Inc (SCNX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Scienture stock rises after adding 12.5M covered lives for Arbli - Investing.com Nigeria
Scienture stock rises after adding 12.5M covered lives for Arbli By Investing.com - Investing.com Australia
Scienture (SCNX) Advances Commercialization of Arbli - GuruFocus
Scienture expands payor coverage for Arbli by 12.5M lives - Investing.com
SCIENTURE Expands Arbli™ Payor Coverage and Commercial Access, Adding Approximately 12.5 Million Covered Lives Nationwide - marketscreener.com
Scienture Holdings Inc (SCNX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Scienture Holdings Inc (SCNX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Scienture Holdings Inc (SCNX) Institutional Confidence - TradingKey
Scienture Holdings Inc (SCNX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Scienture Holdings Inc (SCNX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Scienture Holdings Inc (SCNX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Scienture Holdings Inc (SCNX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Analysts Conflicted on These Healthcare Names: Moderna (MRNA) and Scienture Holdings (SCNX) - The Globe and Mail
Scienture Holdings Inc. (SCNX) Q1 2026 Earnings: EPS Surprise of 64.35% Drives Stock RallyDividend Growth Analysis - dars.gov.et
Scienture Holdings (SCNX) Gains 5.25% as Stock Approaches Key Resistance LevelSingle Stock ETF - dars.gov.et
SCNX Q1 2026 Earnings: Loss Narrower Than Expected as Stock Declines 4.66%Dividend Earnings Report - newsline.com
Exclusive: Scienture expands coverage for opioid overdose treatment ahead of commercial launch - MSN
SCNX Q1 2026 Earnings: Narrower-Than-Expected Loss Boosts SentimentEarnings Weakness Phase - newsline.com
Scienture Holdings (SCNX) Investor Relations, Earnings Summary & Outlook - Quartr
Scienture Holdings (SCNX) Q3 2025 earnings summary - Quartr
Scienture Holdings Inc. (SCNX) Rallies 6.43% to $0.38, Nears Key ResistanceRSI Oversold Picks - newsline.com
Scienture Holdings Inc at Small Cap Showcase & WTR Insights Conference Transcript - GuruFocus
SCNX Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive MomentumCore Business Growth - newsline.com
Scienture’s naloxone nasal spray added to national health plan By Investing.com - Investing.com South Africa
Scienture Holdings, Inc. Secures Formulary Coverage for REZENOPYTM with Large National Health Plan and Expands Commercial Team - marketscreener.com
Scienture’s naloxone nasal spray added to national health plan - Investing.com UK
SCIENTURE Secures Formulary Coverage for REZENOPY™ with a Large National Health Plan and Expands Commercial Team - The Manila Times
Scienture Holdings Inc Stock (SCNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
7.19%
1.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):